English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/184600
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


Validation of the HIV Tropism Test TROCAI Using the Virological Response to a Short-Term Maraviroc Monotherapy Exposure

AuthorsGonzález-Serna, A.; Genebat, Miguel; Luna-Romero, M. de; Tarancón-Díez, Laura; Domínguez-Molina, Beatriz; Pacheco, Yolanda M. CSIC ORCID; Muñoz-Fernandez, M. Angeles; Leal, Manuel CSIC; Ruiz-Mateos, Ezequiel
Issue Date2016
PublisherAmerican Society for Microbiology
CitationAntimicrobial Agents and Chemotherapy 60: 6398-6401 (2016)
AbstractTROCAI is a phenotypic tropism test developed using the virological response to a short-term exposure to maraviroc monotherapy (Maraviroc Clinical Test [MCT]). It was found that with TROCAI, a cutoff of <0.5% of dual/mixed viruses was needed to predict R5 HIV tropism. Here, we have validated TROCAI, using this cutoff, in a new cohort of 42 patients, finding a very high concordance between TROCAI and MCT (98%), and a good concordance (71 to 87%) with other genotypic/phenotypic methods.
Publisher version (URL)https://doi.org/10.1128/AAC.01326-16
Appears in Collections:(IBIS) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf59,24 kBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.